Skip to main content
S&P 5007,709.24+1.85%DOW53,290.92+2.90%NASDAQ25,920.27+2.16%BTC$80,327.00+3.48%ETH$2,425.85+5.66%GOLD$4,078.60+3.51%OIL$87.62-8.81%
Smart Investors Daily
SID Premium
PR

NASDAQ · PRAX

Praxis Precision Medicines, Inc.

Healthcare · Biotechnology

$280.51

Up+$3.29 (+1.17%)

Updated Nov 4, 2026, 5:46 PM

SID Score

5.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
5.65B
P/E ratio
-22.87
Dividend yield
0.00%
52-week range
$236.80 – $392.70
Volume
221.55K
Avg. volume
1.03M

Price performance · PRAX

PRAX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

PRAX closed at $280.51 after 21 trading sessions, up 0.13% for the selected period.

Last close
$280.51
Period change
+0.13%
Period low
$239.02
Period high
$288.62
Daily close
View OHLC price history
PRAX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$277.76$286.035$276.00$280.51221.55K
Nov 2, 2026$286.26$294.95$272.72$273.99312.11K
Oct 30, 2026$283.92$290.06$280.00$285.93306.55K
Oct 29, 2026$282.88$290.22$282.88$288.62508.54K
Oct 28, 2026$269.69$285.76$269.69$285.48335.98K
Oct 27, 2026$267.35$272.20$266.11$267.59388.23K
Oct 26, 2026$256.36$268.08$254.30$267.39389.76K
Oct 23, 2026$256.89$259.03$250.84$252.96371.62K
Oct 22, 2026$253.05$263.82$253.05$258.92355.67K
Oct 21, 2026$266.03$272.00$256.05$256.47497.13K
Oct 20, 2026$259.40$270.33$258.03$264.49886K
Oct 19, 2026$245.42$261.605$244.265$260.17860.78K
Oct 16, 2026$250.11$251.78$241.76$241.76541.79K
Oct 15, 2026$245.28$255.42$239.9025$248.24632.95K
Oct 14, 2026$239.72$245.57$236.795$239.02958.76K
Oct 13, 2026$250.09$252.64$241.53$243.34622.17K
Oct 12, 2026$257.94$259.50$251.21$251.38301.32K
Oct 9, 2026$266.91$267.85$259.00$259.86517.23K
Oct 8, 2026$273.74$273.96$260.07$263.55675.6K
Oct 7, 2026$277.16$285.63$271.2755$278.02444.25K
Oct 6, 2026$289.47$289.47$272.17$280.14435.17K

Latest PRAX news

The latest Smart Investors Daily articles mentioning PRAX.

Stock researchCompany · Overview

PRAX research

Overview

Company profile and research snapshot.

Company profile

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$403.80
Implied upside
—
Analysts
21
PRAX recent ratings
DateFirmRatingTarget
Oct 16, 2026JP MorganOverweight—
Oct 15, 2026HC Wainwright & Co.Buy—
Oct 15, 2026UBSBuy—
Oct 6, 2026BTIGBuy—
Oct 6, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?

Praxis Precision Medicines recently outlined a busy November calendar, with third quarter 2026 results released on November 9 and an Investor Day on November 12 covering commercial plans for ulixacaltamide and relutrigine, alongside slots at several major healthcare conferences. The clustering of earnings, detailed launch preparation updates and prominent conference appearances signals a pivot from a pure R&D focus toward commercial readiness for Praxis Precision Medicines, with...

Yahoo · Oct 27, 2026

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

Company to host an in-person and virtual Investor Day on November 12, 2026BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report financial results for the third quarter ended September 30, 2026, before the financial markets open on Monday, November 9, 2026. The Company also announced details of its upcoming Investor Day and

Yahoo · Oct 18, 2026

Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?

Praxis Precision Medicines has delivered a very large 3 year share price gain, yet recent pullbacks and a shifting business profile now put the spotlight on a more basic question. At today’s price, investors are asking how well Praxis Precision Medicines is supported by its book value compared with the rest of the pharmaceuticals and biotech industry. Over the past 3 years the stock has risen by a very large amount, which puts a lot of weight on whether the underlying net assets can support...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By